The effect of herpes zoster vaccines on incident dementia in England: Protocol for an OpenSAFELY regression discontinuity study

Le résumé fourni par la source

Abstract The English national shingles vaccination programme was officially launched on 1 September 2013 using the live attenuated herpes zoster vaccine Zostavax and updated on 1 September 2023 to replace Zostavax with the two-dose, non-live, recombinant subunit herpes zoster vaccine Shingrix. A study using a regression discontinuity design, conducted following the introduction of the herpes zoster vaccination programme on 1 September 2013 in Wales and using the SAIL databank to analyse Welsh routinely collected data, suggested that Zostavax vaccination reduced the probability of a new dementia diagnosis by approximately 20% over a seven-year follow-up period. The effects of Zostavax and Shingrix on incident dementia in England have not been published to date. This protocol describes a regression discontinuity study to study the effect of herpes zoster vaccines on incident dementia in England using linked electronic health records from OpenSAFELY.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.